

AroCell strengthens the team – recruits a Global Medical Lead

AroCell AB (publ.) announces today that Jonas Söderholm joins the management team as Global Medical Lead. Jonas will lead and develop AroCell's clinical program with a focus on getting more clinical evidence for the use of TK1 as a biomarker in cancer treatment.

Jonas has a Ph.D. in Biomedical Laboratory Science at Karolinska Institutet, supervised by Professor Matti Sällberg, and a Bachelor of Business Administration from the School of Business, Economics, and Law at the University of Gothenburg. He is most recently coming from AbbVie Scandinavia, where he has been working since 2013 on several different positions including Medical Lead, Medical Advisor, and Research Lead in areas such as Gastroenterology, Rheumatology, and Virology. At AbbVie, he has been part of several successful launches of new products. Jonas will report to the CEO and work closely with the rest of the management team to coordinate AroCell's clinical program as well as to spread awareness around the benefit of measuring TK1 with AroCell TK 210 ELISA.

Jonas has deep knowledge within the medical areas as well as in business development. He has extensive experience working closely with "Key Opinion Leaders" (KOLs), conducting clinical studies and generating publications.

"We are very happy to welcome Jonas to the AroCell team. Jonas possesses valuable expertise and experience which are well suited for us. He will unquestionably strengthen our company even further and help us in our efforts to make AroCell TK 210 ELISA available to patients with cancer", says Anders Hultman, CEO of AroCell.

"I'm looking forward to start working at AroCell. It will be exciting to contribute with my experience and to improve the patient care in several types of cancer ", says Jonas Söderholm.

Jonas will start his new position on April 12, 2021.

Contacts

Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Image Attachments

[Jonas Söderholm AroCell AB](#)

Attachments

[AroCell strengthens the team – recruits a Global Medical Lead](#)